ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Innovative γ-Oryzanol and KC2 Based Lipid Nanoparticles: OryKL Platform Provides Safe and Efficient In Vivo mRNA Delivery.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Platelet-Targeted Self-Amplifying mRNA for Safe, Long-Acting Thromboprophylaxis.Circulation research · 2026Article
- CD39 mRNA therapy attenuates localized acute inflammation: A novel anti-inflammatory strategy using cationic nanoliposomes.Molecular therapy. Nucleic acids · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
mRNA nanotherapeutics hold immense potential for treating a wide range of diseases, but their widespread clinical adoption is limited by current lipid nanoparticle (LNP) delivery platforms, which frequently face challenges such as limited biocompatibility, immunogenic response, insufficient mRNA delivery efficacy and stringent cold-chain requirements. In this study, we systematically screened a 20-member lipid mixture library by substituting ionizable lipids and sterol components to identify formulations with improved physicochemical and biological profiles. A lead candidate combining γ-oryzanol and DLin-KC2-DMA as LNPs, termed OryKL (or KO 12 LNPs), was identified, exhibiting spherical bleb-type and core-shell nanostructures (∼150 nm), high mRNA encapsulation, and significantly enhanced in vitro transfection efficiency compared to cholesterol-based controls. Intravenous administration of OryKL delivered Cre recombinase mRNA effectively across multiple organs in Ai9 reporter mice, resulting in distinct cell-level tropism, and no detectable toxicity or inflammation, as confirmed via qPCR, organ histology, hematological assessment and liver function tests. Additionally, OryKL retained transfection potency for at least 60 days in lyophilized form with 20% (w/v) sucrose, supporting ambient-stable storage. These findings establish γ-oryzanol as a promising sterol alternative and position OryKL as a biocompatible, effective, and storage-stable platform for next-generation mRNA therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.